Page 32 - TD-3-3

Tumor Discovery Adjuvant immunotherapy in high-risk melanoma

improved 18-month RFS as compared to placebo (86% vs. Consent for publication
77%; HR = 0.61; 95% CI: 0.45 – 0.82). However, grade ≥3
34
toxicity rates were higher with pembrolizumab compared This retrospective research was carried out using data that
were already available and fully anonymized. As a result,
to placebo (26% vs. 17%). Based on this information, the we did not seek specific consent from the patients. The
FDA has approved adjuvant pembrolizumab for patients use of pre-existing, anonymized data aligns with ethical
with Stage IIB and IIC melanoma following a complete guidelines, eliminating the necessity for individual patient
resection. consent in this context.
5. Conclusion Availability of data

Despite the limitations of our study, including a small patient Data used in this work are available from the corresponding
cohort, the real-world data reinforces the findings from author on reasonable request.
landmark clinical trials regarding the effectiveness and side
effects of adjuvant ICIs therapy in patients with high-risk References
resected stage III and IV malignant cutaneous melanoma. 1. Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining
The encouraging and exciting new developments in the the patient at high risk for melanoma. Int J Dermatol.
melanoma adjuvant treatment landscape suggest potential 2010;49(4):362-376.
transformative impacts in the near future.
doi: 10.1111/j.1365-4632.2010.04381.x
Acknowledgments 2. Available from: https://www.canceraustralia.gov.au/cancer-
types/melanoma/statistics [Last accessed on 2022 Jun 01].
None.
3. Keung EZ, Gershenwald JE. The eighth edition American
Funding joint committee on cancer (AJCC) melanoma staging
system: Implications for melanoma treatment and care.
None. Expert Rev Anticancer Ther. 2018;18(8):775-784.
Conflict of interest doi: 10.1080/14737140.2018.1489246
The authors declare that they have no competing interests. 4. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma
staging: Evidence-based changes in the American joint
Author contributions committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin. 2017;67(6):472-492.
Conceptualization: Mohammad Usman Hakeem, doi: 10.3322/caac.21409
Muhammad Adnan Khattak
Formal Analysis: Gabriela Marsavela 5. Sullivan RJ, Atkins MB, Kirkwood JM, et al. An update
Investigation: Mohammad Usman Hakeem, Afaf Abed on the Society for Immunotherapy of Cancer consensus
Methodology: Mohammad Usman Hakeem, Muhammad statement on tumor immunotherapy for the treatment of
cutaneous melanoma: Version 2.0. J Immunother Cancer.
Adnan Khattak 2018;6(1):44.
Writing – original draft: Mohammad Usman Hakeem
Writing – review & editing: Mohammad Usman Hakeem, doi: 10.1186/s40425-018-0362-6
Muhammad Adnan Khattak, Afaf Abed 6. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283
consecutive patients with metastatic melanoma or renal
Ethics approval and consent to participate cell cancer using high-dose bolus interleukin 2. JAMA.
1994;271(12):907-913.
As this study is retrospective in nature, it focuses on the analysis
of data that has already been collected in the past. Therefore, 7. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose
we did not seek ethics approval for this research. The data used recombinant interleukin 2 therapy for patients with
metastatic melanoma: Analysis of 270 patients treated
in this study were obtained from pre-existing records and between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2105.
did not involve any new data collection or interaction with
participants. Moreover, our study did not involve the analysis doi: 10.1200/jco.1999.17.7.2105
of any biological samples, which would typically necessitate 8. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-
specific ethical considerations and approvals. The absence of dose recombinant interleukin-2 therapy in patients with
such components further reduces the need for formal ethics metastatic melanoma: Long-term survival update. Cancer J
approval. Consequently, our study complies with the ethical Sci Am. 2000;6(Suppl 1):S11-S14.
guidelines for retrospective data analysis. 9. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy

Volume 3 Issue 3 (2024) 8 doi: 10.36922/td.3143